The PRMT5 inhibitor EPZ015666 is effective against HTLV-1-transformed T-cell lines in vitro and in vivo

por Ernzen, Kyle, Melvin, Corrine, Yu, Lianbo, Phelps, Cameron, Niewiesk, Stefan, Green, Patrick L., Panfil, Amanda R.
Publicado 2023

HTLV-1 intragenic viral enhancer influences immortalization phenotype in vitro, but is dispensable for persistence and disease development in animal models

por Maksimova, Victoria, Smith, Susan, Seth, Jaideep, Phelps, Cameron, Niewiesk, Stefan, Satou, Yorifumi, Green, Patrick L., Panfil, Amanda R.
Publicado 2022

HTLV-1 Hbz protein, but not hbz mRNA secondary structure, is critical for viral persistence and disease development

por Maksimova, Victoria, Wilkie, Tasha, Smith, Susan, Phelps, Cameron, Melvin, Corrine, Yu, Lianbo, Niewiesk, Stefan, Green, Patrick L., Panfil, Amanda R.
Publicado 2023